SGH
ORKA

Schonfeld Group Holdings’s Oruka Therapeutics ORKA Stock Holding History

Schonfeld Group Holdings’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-7
Closed -$16K – 410
2013
Q3 		$16K Buy
+7
New +$14.6K 0.03% 120

Other funds holding ORKA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Schonfeld Group Holdings's ORKA Position: Q4 2013 in Review

Schonfeld Group Holdings sold out of Oruka Therapeutics (ORKA) in Q4 2013, closing a stake of 7 shares — an estimated $16K sold.

Schonfeld Group Holdings first reported a position in ORKA in Q3 2013 and held it in 1 quarter. The position peaked at $16K in Q3 2013. 14 funds tracked by Wall St. Rank hold ORKA as of Q4 2013.

  • Schonfeld Group Holdings reported no remaining Oruka Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Schonfeld Group Holdings sold 7 Oruka Therapeutics shares in Q4 2013, an estimated $16K.
  • Schonfeld Group Holdings first reported a position in Oruka Therapeutics in Q3 2013 and held it in 1 quarter.
  • Schonfeld Group Holdings's Oruka Therapeutics position peaked at $16K in Q3 2013.
  • 14 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2013.

Based on Schonfeld Group Holdings's 13F filing for Q4 2013, filed 14 Feb 2014.